Generate:Biomedicines's banner
Generate:Biomedicines's profile picture

Generate:Biomedicines

@generate_biomed6,789 subscribers

As pioneers in generative biology, we're revolutionizing the way biotherapeutics are discovered and developed.

Shorts

Today we announced that we raised $273 million in Series C financing to advance our preclinical & clinical pipeline. We’re proud to have the confidence of our investors, including all Series B investors, who believe we are revolutionizing drug development:

Today we announced that we raised $273 million in Series C financing to advance our preclinical & clinical pipeline. We’re proud to have the confidence of our investors, including all Series B investors, who believe we are revolutionizing drug development:

31,631 görüntüleme

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function. This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development. Learn more:

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function. This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development. Learn more:

10,481 görüntüleme

Videos

Daha fazla içerik yok.